The stock's rise snapped a three-day losing streak.

Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Pre-earnings options volume in Edwards Lifesciences (EW) is normal with calls leading puts 9:2. Implied volatility suggests the market is ...

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...

Stratos Wealth Partners LTD. lowered its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.0% ...

For the quarter ended December 2024, Edwards Lifesciences (EW) reported revenue of $1.39 billion, down 9.7% over the same period last year. EPS came in at $0.59, compared to $0.64 in the year-ago ...

In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...